Naslov
Sodium glucose transporter 2 (SGLT-2) inhibitors and ketoacidosis: is there a link?

Autori
Bulum, Tomislav

Izvornik
Diabetologia Croatica (0351-0042) 43 (2014); 81-83

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni

Ključne riječi
SGLT-2 inhibitors; ketoacidosis

Sažetak
In patients treated with SGLT-2 inhibitors, closer monitoring for ketones might be essential to prevent DKA, a potential life-threatening complication. Since insulinopenia is the most important underlying risk factor for DKA in patients treated with SGLT-2 inhibitors, accurate diagnosis of diabetes type is essential in cases where SGLT inhibition is being considered, to avoid inappropriate patient exposure to these drugs. In my opinion, if we follow guidelines and indication for SGLT-2 inhibitors and prescribe those agents only to type 2 diabetic patients with preserved beta-cell function (not type 1, LADA or patients with secondary diabetes), without kidney failure, acute illness, genitourinary infection and volume depletion, the risk of DKA will be minimal or absent. However, if we do not follow those guidelines, the risk of DKA with SGLT-2 inhibitors will be the reality as described in previous case reports.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA